Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$25.06 USD
+1.49 (6.32%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $25.02 -0.04 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
FLGT 25.06 +1.49(6.32%)
Will FLGT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FLGT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FLGT
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
FLGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
American Well Corporation (AMWL) Reports Q1 Loss, Misses Revenue Estimates
Privia Health (PRVA) Misses Q4 Earnings Estimates
Other News for FLGT
Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript
Fulgent Reports Second Quarter 2024 Financial Results
Fulgent Genetics Inc (FLGT) Q2 2024 Earnings: EPS of ($0.29) Beats Estimates, Revenue of $71. ...
Fulgent Genetics Releases Updated Investor Presentation
Fulgent Genetics raises FY24 EPS view to (30c) from ($1.05), consensus (92c)